5-甲基-2-苯基-1H-咪唑-4-羧酸 | 28824-94-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-2-苯基-1H-咪唑-4-羧酸
• 中文别名: 5-甲基-2-苯-1H-咪唑-4-羧酸
• 英文名称: 4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid
• 英文别名: 5-methyl-2-phenyl-1(3)H-imidazole-4-carboxylic acid；5-methyl-2-phenyl-1H-imidazole-4-carboxylic acid；5(4)-Methyl-2-phenyl-4(5)-imidazol-carbonsaeure
• CAS: 28824-94-4
• 化学式: C₁₁H₁₀N₂O₂
• mdl: MFCD08276055
• 分子量: 202.213
• InChiKey: NEDPOZZCAYIDNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-甲基-2-苯基-1H-咪唑-4-羧酸 生成 4-甲基-2-苯基咪唑
  参考文献：
  名称：

  400. 4-氰基-恶唑的合成

  摘要：

  DOI：

  10.1039/jr9480001969
• 作为产物：
  描述：

  Methyl benzimidate 在 氢氧化钾 、 溶剂黄146 作用下， 生成 5-甲基-2-苯基-1H-咪唑-4-羧酸
  参考文献：
  名称：

  400. 4-氰基-恶唑的合成

  摘要：

  DOI：

  10.1039/jr9480001969

文献信息

• Compounds useful in therapy
  申请人：Bryans Stephen Justin

  公开号：US20050154024A1

  公开（公告）日：2005-07-14

  Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: X represents —[CH 2 ] a —R or —[CH 2 ] a —O—[CH 2 ] b —R; a represents a number selected from 0 to 6; b represents a number selected from 0 to 6; R represents H, CF 3 or Het; Het represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; Y represents one or more substituents independently selected from —[O] c —[CH 2 ] d —R 1 , which may be the same or different at each occurrence; c at each occurrence independently represents a number selected from 0 or 1; d at each occurrence independently represents a number selected from 0 to 6; R 1 at each occurrence independently represents H, halo, CF 3 , CN or Het 1 ; Het 1 at each occurrence independently represents a 5- or 6-membered unsaturated heterocyclic ring; V represents a direct link or —O—; Ring A represents an optionally substituted 5- to 7-membered saturated heterocyclic ring, or a phenylene group; Q represents a direct link or —N(R 2 )—; R 2 represents hydrogen or C 1-6 alkyl; Z represents —[O] e —[CH 2 ] f —R 3 , a phenyl ring (optionally fused to a benzene ring or Het 2 , and the group as a whole being optionally substituted), or Het 3 (optionally fused to an benzene ring or Het 4 , and the group as a whole being optionally substituted); R 3 represents C 1-6 alkyl (optionally substituted), C 3-6 cycloalkyl, C 3-6 cycloalkenyl, phenyl (optionally substituted), Het 5 or NR 4 R 5 ; e represents a number selected from 0 or 1; f represents a number selected from 0 to 6; Het 2 and Het 5 independently represent optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic rings; Het 3 represents an optionally substituted 4 to 6-membered saturated, partially saturated or aromatic heterocyclic ring; Het 4 represents an optionally substituted 6-membered aromatic heterocyclic ring; R 4 and R 5 independently represent optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-8 cycloalkyl (optionally fused to C 3-8 cycloalkyl), Het 6 , or hydrogen; Het 6 represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; are useful for treating a disorder for which a V1 a antagonist is indicated.

  式(I)的化合物，或其药学上可接受的衍生物，其中： X代表—[CH 2 ] a —R或—[CH 2 ] a —O—[CH 2 ] b —R；a代表从0到6中选择的数字；b代表从0到6中选择的数字； R代表H，CF 3 或Het；Het代表一个可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环； Y代表一个或多个取代基，独立地选择自—[O] c —[CH 2 ] d —R 1 ，每次出现时可能相同也可能不同；c在每次出现时独立地代表从0或1中选择的数字；d在每次出现时独立地代表从0到6中选择的数字； R 1 在每次出现时独立地代表H，卤素，CF 3 ，CN或Het 1 ； Het 1 在每次出现时独立地代表一个5-或6-成员不饱和杂环环；V代表一个直链或—O—；环A代表一个可选择取代的5-到7-成员饱和杂环环，或一个苯基团； Q代表一个直链或—N(R 2 )—； R 2 代表氢或C 1-6 烷基； Z代表—[O] e —[CH 2 ] f —R 3 ，一个苯环（可选择与苯环或Het 2 融合，并且整体作为可选择取代的团），或Het 3 （可选择与苯环或Het 4 融合，并且整体作为可选择取代的团）； R 3 代表C 1-6 烷基（可选择取代），C 3-6 环烷基，C 3-6 环烯基，苯基（可选择取代），Het 5 或NR 4 R 5 ；e代表从0或1中选择的数字；f代表从0到6中选择的数字； Het 2 和Het 5 独立地代表可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环； Het 3 代表一个可选择取代的4到6-成员饱和、部分饱和或芳香杂环环； Het 4 代表一个可选择取代的6-成员芳香杂环环； R 4 和R 5 独立地代表可选择取代的C 1-6 烷基，C 1-6 烷氧基，C 3-8 环烷基（可与C 3-8 环烷基融合），Het 6 ，或氢； Het 6 代表一个可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环；适用于治疗需要V1 a 拮抗剂的紊乱。
• Compounds Useful In Therapy
  申请人：Bryans Justin Stephen

  公开号：US20100317652A1

  公开（公告）日：2010-12-16

  The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y′ are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.

  本发明提供了式(I)的化合物或其药学上可接受的衍生物，其中变量Z，Q，环A，V，X，Y和Y'如此定义，并且包含这些化合物的药物组合物。式(I)的化合物和包含它们的药物组合物可用于治疗需要V1a拮抗剂的紊乱，特别是痛经。
• Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution
  作者：Andrew Potter、Victoria Oldfield、Claire Nunns、Christophe Fromont、Stuart Ray、Christopher J. Northfield、Christopher J. Bryant、Simon F. Scrace、David Robinson、Natalia Matossova、Lisa Baker、Pawel Dokurno、Allan E. Surgenor、Ben Davis、Christine M. Richardson、James B. Murray、Jonathan D. Moore

  DOI：10.1016/j.bmcl.2010.09.063

  日期：2010.11

  Pin1 is an emerging oncology target strongly implicated in Ras and ErbB2-mediated tumourigenesis. Pin1 isomerizes bonds linking phospho-serine/threonine moieties to proline enabling it to play a key role in proline-directed kinase signalling. Here we report a novel series of Pin1 inhibitors based on a phenyl imidazole acid core that contains sub-mu M inhibitors. Compounds have been identified that block prostate cancer cell growth under conditions where Pin1 is essential. (C) 2010 Elsevier Ltd. All rights reserved.
• Chemoselective Arylamidine Cyclizations:  Mild Formation of 2-Arylimidazole-4-carboxylic Acids
  作者：Joshua C. Yoburn、Subramanian Baskaran

  DOI：10.1021/ol0514855

  日期：2005.8.1

  A versatile, one-pot synthesis of 2-arylimidazole-4-carboxylic acids from arylamidines and methyl-2-chloroacetoacetate is described. The transformation is chemoselective, and reaction conditions are mild. Moreover, the flexibility of the strategy offers rapid access to two important classes of biaryl compounds, both 2-arylimidazoles and 2-arylpyrimidines, depending simply upon solvent and base selection.
• EP1093367A4
  申请人：——

  公开号：EP1093367A4

  公开（公告）日：2003-03-05